NSE: PFIZER · BSE: 500680
PFIZER LTD
Sells pharmaceutical products in India, generating Rs 2,519.65 crore in revenue in FY26, up 10.4% year-on-year with net profit of Rs 722.43 crore. The product range includes the hormone-based menopause therapy Premarin Vaginal Cream, an imported product that contributes less than 1% of revenue. Q1 FY27 revenue was Rs 653.17 crore, up 8.3% year-on-year, with net profit of Rs 204.47 crore. Employee costs are the largest operating expense at 14.6% of revenue, with materials at 12.3% and other operating expenses at 14.4%. Capital expenditure was 1.0% of revenue in FY26, and the company has no subsidiaries, has operated for 75 years, and declared a Rs 75 per share dividend for the year. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceutical products, Premarin Vaginal Cream (1%). Established, asset-light Indian pharmaceutical company that imports and sells products; no subsidiaries.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 2,611 | 2,425 | 2,193 | 2,281 | 2,520 |
| EBITDA (ex other income) | 836 | 842 | 643 | 913 | 855 |
| margin % | 32.0 | 34.7 | 29.3 | 40.0 | 33.9 |
| Owners' profit | 613 | 624 | 551 | 768 | 722 |
| EPS, as reported (₹) | 133.89 | 136.38 | 120.51 | 167.79 | 157.92 |
| ROE % · ROCE % | 21.4 · 25.7 | 19.5 · 25.0 | 15.3 · 20.7 | 18.2 · 23.6 | 17.2 · 22.9 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 667 | 356 | 257 | 660 | 968 |
| Capex | (15) | (65) | (19) | (28) | (25) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 589 | 538 | 592 | 603 | 1,245 | 645 | 629 | 653 |
| Profit before tax | 215 | 172 | 426 | 260 | 515 | 192 | 269 | 277 |
| Net profit | 158 | 128 | 331 | 192 | 381 | 142 | 200 | 204 |
| EPS (₹) | 34.61 | 27.89 | 72.34 | 41.91 | 83.23 | 31.01 | 43.68 | 44.69 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,20,165 | 34.8 | 5.01 | 22.5 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,51,896 | 86.3 | 15.03 | 65.0 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,56,538 | 73.9 | 8.90 | 38.9 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,17,055 | 26.1 | 3.96 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| LAURUS LABS LIMITED | 1,15,722 | 105.7 | 21.31 | 64.4 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 1,09,385 | 33.9 | 2.86 | 14.6 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,09,060 | 32.3 | 3.16 | 16.7 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,03,353 | 50.6 | 6.24 | 28.4 | 11.7 | 10.8 | — | 27.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 18.4 | 30.1 | 45 of 158 | 72% |
| P/B | 4.0 | 3.0 | 100 of 163 | 39% |
| ROCE | 22.7 | 10.8 | 22 of 183 | 89% |
| ROE | 17.2 | 9.8 | 33 of 166 | 81% |
| Debt / Equity | 0.0 | 0.2 | 37 of 166 | 78% |
| EBITDA margin | 44.8 | 17.5 | 6 of 165 | 97% |
| Revenue growth | 8.3 | 16.3 | 100 of 161 | 38% |
| Profit growth | 6.6 | 30.9 | 104 of 158 | 34% |
| Market cap | 17010 | 810 | 31 of 181 | 83% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 26 Oct 2026 · Board meeting set for November 3 to approve quarterly and half-year results | results | low | — | — |
| 9 Oct 2026 · Pfizer files quarterly dematerialization compliance certificate | compliance | minimal | — | — |
| 2 Oct 2026 · Newspaper ad on SEBI special window for physical share transfers | compliance | minimal | — | — |
| 29 Sept 2026 · Trading Window Closure for Half-Yearly Financial Results | compliance | minimal | — | — |
| 29 Sept 2026 · Pfizer gets Rs 1.26 cr tax penalty on transfer pricing audit | regulatory legal | high | — | — |
| 18 Sept 2026 · Pfizer India Senior Director Sharad Goswami resigns effective Sep 25 | management changes | medium | — | — |
| 7 Sept 2026 · Pfizer to discontinue Minipress XL, receives Rs 131 Cr from parent | business updates | medium | — | — |
| 4 Aug 2026 · Pfizer informs about newspaper ad on physical shares re-lodgement window | compliance | minimal | — | — |
| 29 Jul 2026 · Pfizer AGM 2026: All resolutions passed; Rs 75 final dividend confirmed | board shareholder meetings | low | — | — |
| 28 Jul 2026 · Pfizer 75th AGM: Rs 75 dividend declared, FY26 results adopted | board shareholder meetings | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.